CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer

Abstract

CD24 is associated with unfavourable prognoses in various cancers, but the prevalence of CD24 expression and its influence on clinical outcome in subtypes of breast cancers remain unclear. CD24 expression was analyzed by immunohistochemistry in 747 breast cancer tissues, and DNA methylation and histone modification status in the promoter region of CD24 were assessed using bisulfite sequencing and chromatin immunoprecipitation assay. 213 (28.5%) samples exhibited high CD24 expression in the membrane and/or cytoplasm of breast cancer cells, and CD24 overexpression was significantly correlated with the presence of lymph node metastasis and more advanced pathological stage. Patients with CD24-high tumours had significantly shorter patient survival than those with CD24-low tumours. Importantly, multivariate analysis that included tumour size, lymph node metastasis and chemotherapy demonstrated that high CD24 expression is independently associated with poorer survival in luminal A and triple-negative breast cancer (TNBC) subtypes. Furthermore, CD24 gene expression was associated with histone acetylation independent of DNA methylation, suggesting its epigenetic regulation in breast cancer. Our results suggest that CD24 overexpression is an independent unfavourable prognostic factor in breast cancer, especially for luminal A and TNBC subtypes, and CD24 may be a promising therapeutic target for specific subtypes of breast cancer.

Efficacy of Palonosetron vs. Ramosetron for the Prevention of Postoperative Nausea and Vomiting: A Meta-Analysis of Randomized Controlled Trials

“…However, due to the lack of data, it is difficult to definitely say that a difference in side-effect profile between palonosetron and ramosetron does not exist. None of the studies included in the present meta-analysis reported any severe cardiac adverse events, such as QT prolongation or fatal arrhythmias, which corresponds to the results of previous studies that reported the safety of palonosetron and ramosteron on the QT interval 30313233…”

CD24 blunts oral squamous cancer development and dampens the functional expansion of myeloid-derived suppressor cells

“…[10][11][12] Elevated CD24 expression has been observed on many types of cancer cells, including breast, ovary, bladder, prostate, and uterine cervical cancer, and is associated with tumor growth and progression. [13][14][15][16][17][18] In the present study, we sought to gain more insight into the role of CD24 in oral cancer. In contrast to other cancers, we found that higher CD24 expression level in the tumor microenvironment confers better survival in oral cancer patients.…”

Risk Factors contributing to Methylation Shifts in BRCA1 and associated genes in African Americans with Triple Negative Breast Cancer

“…But when observing changes in histone acetylation there have been multiple findings recently that point to this having an effect as well. Kwon and colleagues discovered a correlation between histone acetylation and CD24, which leads to an unfavorable prognosis in TNBC through hypoacetylation [40]. Although these are only a few genes responsible for TNBC this paints a picture on what role methylation and acetylation play in altering TNBC probability.…”